Altria Group, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MO research report →
Range $58 – $79
Price Chart
About the company
Operating across the United States through its subsidiaries, Altria Group, Inc. is a prominent manufacturer and marketer of both combustible and oral tobacco items. Its portfolio features cigarettes, primarily under the iconic Marlboro brand, alongside cigars and pipe tobacco mainly offered as Black & Mild.
- CEO
- Salvatore Mancuso
- IPO
- 1985
- Employees
- 5,900
- HQ
- Richmond, VA, US
AI snapshot
Six angles, distilled from the data.
The stock is in a steady, range-bound uptrend rather than a breakout phase. It sits above the 200-day average at 67.19 and near the upper half of its 52-week range, with the 50-day average just above the 200-day line, signaling a mature but constructive regime.
Street sentiment is constructive but not euphoric. Consensus sits at Buy with a 71.33 target, modestly above the current share price, and recent action has been mixed: UBS stayed positive while Barclays cut its target to $58, keeping the range wide.
The next print has a mixed setup. MO has beaten EPS in 4 of the last 7 quarters, and next-year EPS is modeled higher at 5.864 versus 4.77 TTM. Shareholders should watch whether pricing power and volume stability can offset the recent uneven beat rate.
Recent insider activity leans to net selling, but most of the board activity is award-related and not a trading signal. The clearest discretionary moves were director sales in May and a larger officer sale in March, partially offset by one director purchase in September.
Profitability remains strong, with an 87.0% gross margin and a 76.36% operating margin. Growth is modest, with revenue up 1.2% year over year and earnings down 2.7%, while free cash flow of $9.51 billion and an 8.24% FCF yield support the cash profile.
MO still screens as a high-margin, cash-generative tobacco name with a lower-beta profile than the broader market. At 12.44x earnings, it trades at a restrained valuation for the sector, reflecting slower growth and balance-sheet leverage.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $113.34B
- P/E
- 14.32
- Fwd P/E
- 11.95
- PEG
- -1.69
- P/S
- 5.18
- P/B
- -42.54
- EV/EBITDA
- 11.54
- Div Yield
- 6.32%
- Gross Margin
- 70.99%
- Op Margin
- 55.95%
- Net Margin
- 36.46%
- ROE
- -265.17%
- ROIC
- 36.68%
Latest fiscal year · YoY change
- Revenue
- $20.14B-1.5%
- Gross Profit
- $14.54B+1.2%
- Op Income
- $12.04B
- Net Income
- $6.95B-38.3%
- EPS
- $4.11-37.2%
- OCF Growth
- +6.1%
- FCF Growth
- +5.4%
- 52W High
- $77.06
- 52W Low
- $54.70
- 50D MA
- $68.43
- 200D MA
- $67.36
- Beta
- 0.49
- RSI (14)
- 46
- Avg Volume
- 8.39M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Altria delivered a strong first half, narrowed full-year EPS guidance, and said smoke-free growth, stable premium cigarette pricing, and tighter illicit-product enforcement are supporting the outlook.· July 30, 2026
- Adjusted diluted EPS rose 2.8% to $1.48 in Q2 and 4.9% to $2.80 in the first half.
- Full-year 2026 adjusted EPS guidance was narrowed to $5.61-$5.72, up 3.5%-5.5% versus $5.42 in 2025.
- Smokeable products remained the main earnings driver, with adjusted OCI up 2.4% to $3.0 billion in Q2 and margin expanding to 64.8%.
- on! PLUS is scaling: 49.9 million cans shipped in Q2, retail share reached 8.6%, and national 12 mg and new flavors are planned.
- Management said cigarette volume declines are moderating, helped by tougher enforcement against illicit e-vapor products and less cross-category switching.
Altria reported adjusted diluted EPS of $1.48 in Q2, up 2.8% year over year, and $2.80 for the first half, up 4.9%. Smokeable products adjusted OCI rose 2.4% to $3.0 billion in Q2 and 4.2% to $5.7 billion in the first half, with adjusted OCI margins of 64.8% and 64.9%, respectively. Reported domestic cigarette volumes declined 3.2% in Q2 and 2.8% in the first half; when adjusted for trade inventory movements, declines were estimated at 4.5% and 4.0%. Oral Tobacco Products adjusted OCI fell 8% in Q2 and 4.2% in the first half, while ABI adjusted equity earnings rose 21.5% to $158 million. Management raised the low end of 2026 adjusted EPS guidance and now expects $5.61 to $5.72, implying 3.5% to 5.5% growth versus a 2025 base of $5.42.
Sal Mancuso said the company is executing on three priorities: advancing the smoke-free portfolio, defending profitability in traditional tobacco, and returning capital to shareholders. He highlighted on! PLUS expansion to 120,000 stores, early traction from the product, and planned line extensions later this year, while also pointing to Marlboro Cowboy Cut as a value option that fits the brand’s American heritage. His tone was confident but measured, repeatedly noting that consumers remain under economic pressure and that second-half investments will rise as the company supports launches.
Heather Newman emphasized that first-half results were strong enough to justify narrowing full-year guidance. She cited Q2 adjusted EPS of $1.48, smokeable OCI of $3.0 billion, smokeable OCI margin of 64.8%, Oral Tobacco Products OCI margin of 66.7%, and ABI adjusted equity earnings of $158 million. She also said Altria returned about $3.6 billion in dividends and repurchased 5.3 million shares for $335 million in the first half, ended Q2 with $665 million remaining under the buyback program, and had a debt-to-EBITDA ratio of 1.9x, in line with the roughly 2x target.
Analysts focused on why the second-half EPS setup is not above the strong first-half pace, with management saying timing differences, higher investment for on! PLUS extensions, and duty drawback timing explain the pattern. On cigarettes, management said volume declines are moderating because cross-category switching into illicit e-vapor appears to be slowing as enforcement improves, even as gas prices and inflation still pressure consumers. On on! PLUS, management said the brand is gaining share, the soft-pouch format is resonating, and new 12 mg and flavor extensions should support further growth, though Q2 shipments were affected by prior-year comparisons and launch timing.
The call’s bullish case is that Altria is simultaneously protecting legacy cash flows and building a smoke-free growth platform. Management pointed to on! PLUS share gains, broader distribution, stronger brand awareness, and a more constructive FDA/enforcement backdrop that could help future launches. They also highlighted resilient Marlboro premium leadership, disciplined discount participation through Basic, and continued strong shareholder returns.
The main risks discussed were continued consumer pressure, especially from inflation and high gas prices, and the possibility that second-half trends do not fully match first-half strength. Oral Tobacco Products OCI fell year over year, cigarette volumes still declined, and management acknowledged that Basic-driven discount growth and on! promotional investments could weigh on mix and near-term earnings. In vape, management still faces a prevalent illicit market and said any re-entry into the category will be disciplined and not yet timed.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.8%
- Shares Outstanding
- 1.67B
- Float Shares
- 1.67B
of shares held by institutions
2,563 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for MO, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Sell | Aug 10, 26 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jan 13, 26 | Filing → |
| Sheri BiggsHouse · SC03 | Sell | Mar 19, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Aug 4, 25 | Filing → |
| Pete SessionsHouse · TX17 | Sell | Sep 10, 24 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Mar 20, 24 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Feb 13, 24 | Filing → |
| Virginia Ann FoxxHouse · NC05 | Buy | Jan 11, 24 | Filing → |
| Virginia Ann FoxxHouse · NC05 | Sell | Jan 16, 24 | Filing → |
| Virginia Ann FoxxHouse · NC05 | Sell | Jan 10, 24 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 10, 24 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jan 10, 24 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Oct 10, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 160.98M | ▲ 1.90M |
| Blackrock, Inc. | 126.07M | ▲ 1.33M |
| Vanguard Capital Management LLC | 109.03M | ▲ 196.91K |
| State Street Corp | 70.19M | ▼ 1.60M |
| Sixth Street Partners Management Company, L.P. | 59.12M | ▲ 59.12M |
| Charles Schwab Investment Management Inc | 59.12M | ▲ 4.84M |
| Capital Research Global Investors | 58.65M | ▲ 32.97M |
| Geode Capital Management, LLC | 47.72M | ▲ 699.21K |
| Vanguard Portfolio Management LLC | 33.72M | ▼ 1.49M |
| Gqg Partners LLC | 25.11M | ▲ 1.27M |
| Morgan Stanley | 22.70M | ▼ 1.75M |
| Ameriprise Financial Inc | 22.05M | ▲ 544.33K |
Held by 1,304 ETFs
Biggest fund positions in MO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 9, 26 | McQUADE KATHRYN B. | buy | 1,500 |
| Aug 27, 26 | Presley Steven W. | other | 0 |
| May 26, 26 | KELLY ENNIS DEBRA J | sell | 5,790 |
| May 26, 26 | Strahlman Ellen R | sell | 2,000 |
| May 14, 26 | Strahlman Ellen R | other | 2,571 |
| May 14, 26 | Stoddart Richard S | other | 2,571 |
| May 14, 26 | Clarke Ian L.T. | other | 2,571 |
| May 14, 26 | Connelly Marjorie Mary | other | 2,571 |
| May 14, 26 | KELLY ENNIS DEBRA J | other | 2,571 |
| May 14, 26 | Davis Robert Matthews | other | 2,571 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MO coverage
Recent articles, reports, and earnings notes.

Altria Group (MO): Cash Flow, Pouches, and Cigarette Decline
Altria combines strong cash generation and Marlboro pricing power with a growing on! pouch franchise, but cigarette volume declines and leverage keep the stock in Hold territory.

Altria Group, Inc. (MO) drops 8% after Q2 EPS miss
Altria Group, Inc. (MO) drops after reporting second-quarter results that missed profit expectations. Revenue edged higher, but weaker adjusted EPS and a cautious outlook pressured the stock, even as the company’s dividend yield remains attractive for income investors.
Want a deeper read on MO?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Wall Street's Most Accurate Analysts Spotlight On 3 Defensive Stocks Delivering High-Dividend Yields
benzinga.com · Oct 5
4 of the Safest Ultra-High-Yield Dividend Stocks You Can Confidently Buy Today
247wallst.com · Oct 3
Dividend Champion, Contender, And Challenger Highlights: Week October 4
seekingalpha.com · Oct 2
MO Looks Cheap Until You See the Numbers: Negative Equity, Crumbling Margins, and a Dividend About to Break
247wallst.com · Oct 2
6 High-Yield Stocks Where the Market May Be Warning of a Dividend Cut
247wallst.com · Oct 1
Treasury Yields Are Above 5%. These 4 Dividend Stocks Still Make the Cut
247wallst.com · Oct 1
A $500,000 Roth Portfolio Loaded With These Dividend Stocks Pays $40,000 a Year and the IRS Gets None of It
247wallst.com · Oct 1
Altria (MO) Dips More Than Broader Market: What You Should Know
zacks.com · Sep 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed September 29, 2026 · Live quote · Not investment advice